Longer lead-times to achieve Chinese regulatory approval makes this sector more challenging to support. That said, CIC has been successful in obtaining cash investment into generics as well as specialist biotech firms. Our network in the Chinese pharmaceutical sector makes us an initial point of call for UK firms seeking to open up the Chinese market.